February 4, 2025
Argenica Therapeutics (ASX:AGN) advances breakthrough TBI treatment with promising preclinical results
Argenica Therapeutics’ ARG-007 has demonstrated compelling neuroprotective effects in preclinical models of traumatic brain injury, reducing brain cell damage and neuroinflammation to levels comparable with non-injured subjects.